SCOTTSDALE, Ariz., June 28 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. , today announced an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), which is a component of the National Institutes of Health (NIH). The agreement states that the NIAID will fund and conduct a preclinical anti-microbial evaluation of ImmuneRegen’s proprietary compound Viprovex(TM) for potential use as a possible treatment for certain infectious respiratory diseases including influenza, measles and SARS.
The NIAID offers both in vitro and animal model evaluation services to help facilitate the rapid development and commercialization of products for the treatment of infectious diseases. The evaluation will be conducted through NIAID contracted testing laboratories and is under the authority of the Public Health Service Act, chapter 373, title III.
About Viprovex
Viprovex is the trade name used in referring to formulations of Homspera for potential indications for treatment of maladies caused by exposure to various chemical and biological agents. Homspera is a generic name used by the Company to describe the synthetic peptide Sar9, Met (O2)11-Substance P. Sar9, Met (O2)11-Substance P is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species. All of the Company’s research and development efforts are early, pre-clinical stage and both Homspera and Viprovex have only undergone exploratory studies to evaluate their biological activity in small animals.
About ImmuneRegen BioSciences, Inc.
IR BioSciences Holdings Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera(TM) and its derivatives Radilex(TM) and Viprovex(TM), which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera is derived from modified Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and the stimulation of the human immune system. For more information, please visit the company’s website at www.immuneregen.com.
Statements about the Company’s future expectations, including statements about the potential for the Company’s drug candidates, science and technology, and all other statements in this press release other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with the Company’s business, are subject to various risks and uncertainties. The Company’s actual results could differ materially from expected results as a result of a number of factors, including, the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs, (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials) the evaluation of potential opportunities, the level of corporate expenditures, capital market conditions, and others set forth in the Company’s periodic report on Form 10-Q for the three months ended March 31, 2006 as filed with the Securities and Exchange Commission. There are no guarantees that any of the Company’s proposed products will prove to be commercially successful. The Company undertakes no duty to update forward-looking statements.
Contact: W. Jason Grimley Senior Account Executive Spelling Communications 310-477-9500 jgrimley@spellcom.com
ImmuneRegen BioSciences, Inc.
CONTACT: W. Jason Grimley, Senior Account Executive of SpellingCommunications, +1-310-477-9500, jgrimley@spellcom.com, for ImmuneRegenBioSciences, Inc.
Web site: http://www.immuneregen.com//
